(MENAFN- Investor Brand Network) 180 life sciences (nasdaq: atnf) , a clinical-stage biotechnology company, has announced the publication of a review written by Professor Jagdeep Nanchahal, chair of ATNF's medical advisory board; the review was also written by a colleague of Nanchahal's from the University of Oxford. Titled“Treatments for early stage Dupuytren's disease: An evidence-based approach,”
the article was published inthe European volume of the“Journal of Hand Surgery.”
In the publication, the two authors describe the limitations of current treatments for late-stage Dupuytren's disease as well as the lack of evidence based on randomized double blind, placebo-controlled trials for treatments for early-stage disease, such as intranodular injection of steroid or radiotherapy. The authors also describe how tumor necrosis factor (“TNF”) was identified“as a potential therapeutic target through the study of cellular signaling mechanisms in tissue from patients.” In addition, they talk about the results of the phase 2a dose ranging trial and the phase 2b trial. The review summarizes evidence for current treatments for early-stage Dupuytren's disease based on systematic reviews of literature and advances made by Nanchahal and his University of Oxford team.“We look forward to advancing the laboratory and clinical findings that support the potential for anti-TNF to treat the large number of patients with early-stage Dupuytren's disease,” said 180 Life Sciences CEO Dr. James Woody in the press release.
To view the full press release, visit
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company driving groundbreaking studies into clinical programs that are seeking to address major unmet medical needs. The company's focus is a novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). For more information about the company, visit
.
NOTE TO INVESTORS:
The latest news and updates relating to ATNF are available in the company's newsroom at
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you'll need to ensure that your next press release grabs the attention of your target audience and doesn't let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire's syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
InvestorWire is part of the
investorbrandnetwork .
MENAFN25012023000224011066ID1105476885
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.